Revier has established the first therapeutic approach to selectively target Class IIa HDACs to treat cardiometabolic diseases. Our orally available small molecules are designed to inhibit the pathogenic enzymatic activity while preserving healthy biological function and avoiding canonical HDAC inhibition. We are advancing a pipeline of novel disease modulators starting with heart failure with preserved ejection fraction (HFpEF) and atherosclerotic cardiovascular disease (ASCVD) as our initial indications. Our goal is to define a new class of treatments that directly improve cardiometabolic health and provide life-saving, long-term benefits for patients with related diseases. Find more information at www.revier.bio.
